CRWD -47.32AMD -19.52AVGO -70.07TVE.TO 0.42BHP -2.18BBD.B.TO -2.15OWL 0.695
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.78
+0.44 (1.74%)
as of Jun 4, 2026, 2:44:12 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY

Pfizer Inc(PFE)

Mar 12, 2002
A great long term hold for growth. Strong pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$39.85

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 08, 2002
Prefers Glaxco Smith Klein.
Photo of David DriscollDavid DriscollUnlock Rating
$40.01

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2002
Prefers this and J&J over Merk. Will eventually give a 15/20% return.
Photo of Brad WillockBrad WillockUnlock Rating
$40.65

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 17, 2002
At a good price. Have a good drug pipeline. A premium company. Earnings growth should be 20% plus.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$40.13

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
(Was a top pick on June 14 down 5%) Has the best patent protection folio. Should grow 25% in 2002 and 15% for the next two years.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.60

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
They have a good product line plus good new product development is excellent. Very cheap now.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.60

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 08, 2002
Good pipeline. Likes the price.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$39.59

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2002
Likes the pharmaceutical sector. Has a good pipeline for its drugs.
Photo of Neil MurdockNeil MurdockUnlock Rating
$39.70

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2002
Likes the sector. Well positioned. Prefers over Merc.
Photo of John ZechnerJohn ZechnerUnlock Rating
$39.40

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 03, 2002
(Was a top pick on Sept 26 up 3.5%) Will have to buy some biotechs to keep their pipelines growing.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.70

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 02, 2002
(Was a top pick on Sept 10 up 4.4%) Not the best time to buy pharmaceuticals. Buy under $40.
Photo of Brad WillockBrad WillockUnlock Rating
$39.90

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 28, 2001
Very expensive. US drug companies are having problems.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$40.40

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 19, 2001
Good cash flow. Will grow 20% + 2002/03 and 15% 2004. A good price.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$41.10

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 17, 2001
Excellent company. Good dividends.
Photo of Bob StodgellBob StodgellUnlock Rating
$40.33

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 12, 2001
Great company, but economy is hitting all drug companies. Too high now.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$40.24

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 826 to 840 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PANW -10.64$269.79
GS 51.795$1092.8149
AAPL 0.67$310.93
BUG -0.365$36.405
ABBV 5.32$222.45

Today's Top Picks

CRWD -47.32$700.29
AMD -19.52$523
AVGO -70.07$409.16
TVE.TO 0.42$13.99
BHP -2.18$88.67

Popular Articles

Latest Sell Signals

AVGO -70.07$409.16
LDOS 1.85$126.2
CME 0$
ULTA -6.92$464.29
MRVL 10.32$311.97

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica